Shana Carol Neal
Known title: Chief Human Resources OfficerCIK: 0001735118
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Accendra Health Receives NYSE Continued Listing Notice. Accendra Health received a notice from the NYSE regarding continued listing standards, with the company stating its intent to cure the deficiency. This regulatory development adds pressure to a stock that is already trading near its 52-week low. Additionally, Bank of America disclosed a 10.8% stake in the company as of September 30.
Transaction History
| BDX | ▼ Sell | Tax Withholding | 1,146 | $0 | 4/6/2026 | View on chart |
| BDX | ▲ Buy | Grant | 6,727 | $0 | 11/26/2025 | View on chart |
| BDX | ▲ Buy | Grant | 3,525 | $0 | 11/26/2025 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 2,454 | $0 | 11/26/2025 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 1,886 | $0 | 4/4/2025 | View on chart |
| BDX | ▼ Sell | Open Market | 787 | $189K | 1/21/2025 | View on chart |
| BDX | ▼ Sell | Open Market | 788 | $185K | 1/7/2025 | View on chart |
| BDX | ▼ Sell | Open Market | 1,000 | $220K | 12/6/2024 | View on chart |
| BDX | ▲ Buy | Grant | 2,109 | $0 | 11/26/2024 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 509 | $0 | 11/26/2024 | View on chart |
| BDX | ▲ Buy | Option Exercise | 111 | $0 | 11/21/2024 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 32 | $0 | 11/21/2024 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 1,921 | $0 | 4/4/2024 | View on chart |
| BDX | ▲ Buy | Grant | 1,659 | $0 | 11/26/2023 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 258 | $0 | 11/26/2023 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 31 | $0 | 11/20/2023 | View on chart |
| BDX | ▲ Buy | Option Exercise | 110 | $0 | 11/20/2023 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 731 | $0 | 4/4/2023 | View on chart |
| BDX | ▲ Buy | Grant | 8,229 | $0 | 4/4/2023 | View on chart |
| BDX | ▲ Buy | Grant | 1,812 | $0 | 11/26/2022 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 31 | $0 | 11/18/2022 | View on chart |
| BDX | ▲ Buy | Option Exercise | 110 | $0 | 11/18/2022 | View on chart |
| BDX | ▲ Buy | Grant | 7,525 | $0 | 4/6/2022 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 33,489 | $1.4M | 3/4/2022 | View on chart |
| ACH | ▲ Buy | Grant | 68,966 | $0 | 2/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%
The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%. The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.